Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Quest Diagnostics
(NY:
DGX
)
160.55
-1.15 (-0.71%)
Official Closing Price
Updated: 7:00 PM EST, Nov 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Quest Diagnostics
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
How Is The Market Feeling About Quest Diagnostics?
November 11, 2024
Via
Benzinga
Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
November 09, 2024
Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization.
Via
Benzinga
Topics
Government
Exposures
Political
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
October 24, 2024
LabCorp Q3 2024 EPS beats expectations at $3.50, with 7.4% revenue growth to $3.28B. Adjusted EPS guidance revised due to weather.
Via
Benzinga
Topics
Earnings
Exposures
Financial
This Snap Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
October 23, 2024
Via
Benzinga
What Analysts Are Saying About Quest Diagnostics Stock
October 23, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
October 23, 2024
Via
Benzinga
Earnings Preview: Quest Diagnostics
October 21, 2024
Via
Benzinga
Looking Into Quest Diagnostics's Recent Short Interest
October 21, 2024
Via
Benzinga
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
October 22, 2024
Via
Benzinga
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
October 22, 2024
Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, citing acquisitions and new customer wins.
Via
Benzinga
Decoding 7 Analyst Evaluations For Quest Diagnostics
October 07, 2024
Via
Benzinga
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
October 07, 2024
Via
Benzinga
What Analysts Are Saying About Quest Diagnostics Stock
August 27, 2024
Via
Benzinga
Uncovering Dividend Opportunities with NYSE:DGX.
July 25, 2024
Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential.
Via
Chartmill
5 Analysts Assess Quest Diagnostics: What You Need To Know
July 24, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
July 05, 2024
Via
Benzinga
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
August 26, 2024
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing...
Via
Benzinga
8 Health Care Stocks With Whale Alerts In Today's Session
August 01, 2024
Via
Benzinga
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
August 01, 2024
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024...
Via
Benzinga
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
July 23, 2024
Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 revenue...
Via
Benzinga
How Is The Market Feeling About Quest Diagnostics?
June 27, 2024
Via
Benzinga
Peering Into Quest Diagnostics's Recent Short Interest
June 10, 2024
Via
Benzinga
Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday?
July 23, 2024
Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphabet Inc. and Tesla Inc.
Via
Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024
July 23, 2024
DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist
July 23, 2024
The market mood turned jittery after Monday’s rebound, with index futures trading on either side of the unchanged line early Tuesday. The apprehensions reflect uncertainties regarding geopolitics,...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
July 21, 2024
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.
Via
Benzinga
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
July 18, 2024
From
Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via
GlobeNewswire
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
July 18, 2024
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing...
Via
Benzinga
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
July 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.